X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs TORRENT PHARMA - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS TORRENT PHARMA NOVARTIS/
TORRENT PHARMA
 
P/E (TTM) x 295.9 36.7 807.0% View Chart
P/BV x 25.2 5.7 441.2% View Chart
Dividend Yield % 1.4 1.0 151.8%  

Financials

 NOVARTIS   TORRENT PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-17
TORRENT PHARMA
Mar-17
NOVARTIS/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs8551,768 48.4%   
Low Rs6661,186 56.1%   
Sales per share (Unadj.) Rs219.0346.1 63.3%  
Earnings per share (Unadj.) Rs19.155.2 34.6%  
Cash flow per share (Unadj.) Rs20.373.3 27.7%  
Dividends per share (Unadj.) Rs10.0014.00 71.4%  
Dividend yield (eoy) %1.30.9 138.7%  
Book value per share (Unadj.) Rs307.0257.1 119.4%  
Shares outstanding (eoy) m29.96169.22 17.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.54.3 81.4%   
Avg P/E ratio x39.826.8 148.7%  
P/CF ratio (eoy) x37.520.1 186.0%  
Price / Book Value ratio x2.55.7 43.1%  
Dividend payout %52.425.4 206.3%   
Avg Mkt Cap Rs m22,779249,887 9.1%   
No. of employees `0000.711.8 5.7%   
Total wages/salary Rs m1,3939,934 14.0%   
Avg. sales/employee Rs Th9,736.24,971.5 195.8%   
Avg. wages/employee Rs Th2,066.8843.2 245.1%   
Avg. net profit/employee Rs Th849.0792.4 107.1%   
INCOME DATA
Net Sales Rs m6,56258,569 11.2%  
Other income Rs m7022,233 31.4%   
Total revenues Rs m7,26460,802 11.9%   
Gross profit Rs m25913,773 1.9%  
Depreciation Rs m363,069 1.2%   
Interest Rs m72,056 0.4%   
Profit before tax Rs m91710,881 8.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3451,545 22.3%   
Profit after tax Rs m5729,336 6.1%  
Gross profit margin %3.923.5 16.8%  
Effective tax rate %37.614.2 264.9%   
Net profit margin %8.715.9 54.7%  
BALANCE SHEET DATA
Current assets Rs m9,73153,841 18.1%   
Current liabilities Rs m1,83031,612 5.8%   
Net working cap to sales %120.438.0 317.2%  
Current ratio x5.31.7 312.1%  
Inventory Days Days4997 50.1%  
Debtors Days Days2584 30.0%  
Net fixed assets Rs m5742,079 0.1%   
Share capital Rs m141846 16.6%   
"Free" reserves Rs m9,05642,655 21.2%   
Net worth Rs m9,19643,501 21.1%   
Long term debt Rs m022,408 0.0%   
Total assets Rs m11,499101,250 11.4%  
Interest coverage x128.46.3 2,040.3%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.60.6 98.7%   
Return on assets %5.011.3 44.8%  
Return on equity %6.221.5 29.0%  
Return on capital %10.119.6 51.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12920,066 0.6%   
Fx outflow Rs m1,7345,304 32.7%   
Net fx Rs m-1,60514,762 -10.9%   
CASH FLOW
From Operations Rs m-38010,127 -3.7%  
From Investments Rs m4,208-7,869 -53.5%  
From Financial Activity Rs m-3,318-1,918 173.0%  
Net Cashflow Rs m510212 241.2%  

Share Holding

Indian Promoters % 0.0 71.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 7.0 28.5%  
FIIs % 1.6 12.6 12.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 8.8 244.3%  
Shareholders   41,647 26,511 157.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT LTD.  SUVEN LIFE  

Compare NOVARTIS With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7%

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jun 22, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - ASTRAZENECA PHARMA COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS